Signal More than 400 billion dollars of pharma commitments to US facilities create a new AI testbed

Summary

Pharmaceutical companies have committed more than 400 billion dollars to new US research and manufacturing facilities, creating a fresh testbed for AI. CB Insights adds up 2025 announcements from the ten largest committers, with the biggest single pledges reaching 70 billion dollars over the next few years. The investment is being driven by tariff-related reshoring and pressure on supply chains. Because so many facilities are being built at once, the firm sees a reset moment for how laboratories are designed. New labs can be planned around automation and AI from the outset rather than retrofitted later. The buildout thus links trade policy to the pace of AI adoption in drug research.